IRVINE, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- Praxsyn Corporation (OTCQB:PXYN) is pleased to announce their compliance with the new OTC standards, allowing the company to remain on the OTCQB tier. The new procedures for being on the OTCQB tier included an application process with a fee. Praxsyn is pleased to report that they have completed the application process and have paid the required fee.
Praxsyn is eligible to be on the OTCQB tier as the company remains current in their reporting and have undergone the annual verification and management certification process. The designation of Praxsyn on the OTCQB tier improves investor confidence through verified information by confirming the Company Profile is current and complete as well as providing other updated information. The OTC website is also a necessary platform for providing information such as press releases to the company's investor community.
About Praxsyn Corporation
Headquartered in Irvine, California, Praxsyn works to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, a wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek for their patients. Additional company information can be found at www.praxsyn.com.
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) including but not limited to statements regarding the past performance and anticipated results of being on the OTCQB tier of the OTC, and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.
CONTACT: Media/Investor Contact: IR@PraXsyn.com 949-777-6112 ext 101